



ALEMTUZUMAB

Review and update by Cutaneous Lymphoma Foundation's Writers Bureau
November 2023

WHAT IS ALEMTUZUMAB (CAMPATH-1H)?

Brand name: Campath®

Alemtuzumab targets CD52, a protein found on both B and T lymphocytes. By targeting this protein, alemtuzumab signals the immune system to kill lymphoma cells.

HOW IS IT DELIVERED?

Alemtuzumab is given intravenously. It can also be given by injection.

WHAT IS THE EXPECTED RESULT?

Alemtuzumab is not commonly used in skin lymphoma. If it is used, it can reduce lymphoma cells. It might not work in all patients.

ARE THERE SPECIAL CONSIDERATIONS TO BE AWARE OF?

Alemtuzumab can decrease the body's ability to fight infection. When taking alemtuzumab, patients need certain anti-infective drugs to prevent infection.

WHAT ARE COMMON SIDE EFFECTS?

The following is not an exhaustive list of the possible side effects. For a complete list of possible side effects, please see the manufacturer's available information on the specific therapy.

Alemtuzumab can decrease the immune system's ability to fight infection. Also, when given, alemtuzumab can cause an infusion-related reaction (fevers, chills, and other effects). You should talk with your physician in detail about expected side effects.